Publications by authors named "S Zaltron"
Article Synopsis
- Prisons have a higher prevalence of communicable diseases like hepatitis C virus (HCV), necessitating routine testing and direct treatment access for inmates.
- In a study of 5,378 admissions in two prisons in Brescia, 54.5% underwent HCV screening, revealing a 9.2% positivity rate with a significant number showing detectable virus levels.
- Despite 77 treatments being administered, follow-up care for released prisoners was low, indicating a need for better education and improved test-and-treat programs to reduce HCV by 2030 through collaborative efforts with local healthcare services.
Article Synopsis
- The natural history of occult hepatitis B virus infection (OBI) and its reactivation mechanisms remain partially understood, particularly in people living with HIV (PLWH).
- A case study of a co-infected patient illustrated that, despite initial normal liver enzymes, OBI can reactivate after antiretroviral therapy (ART) reintroduction, leading to immune reconstitution inflammatory syndrome (IRIS).
- This highlights the need for heightened vigilance and regular monitoring of HBV markers in immunocompromised patients, even when no hepatitis flare is present.
DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b.
Int J Environ Res Public Health
September 2022
Approved direct antiviral agent (DAA) combinations are associated with high rates of sustained virological response (SVR) and the absence of a detectable hepatitis C viral load 12-24 weeks after treatment discontinuation. However, a low percentage of individuals fail DAA therapy. Here, we report the case of a HIV/HBV/HCV co-infected patient who failed to respond to DAA pangenotypic combination therapy.
View Article and Find Full Text PDFBackground: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking.
Aim: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD).
Methods: All HCV patients treated with DAA in Lombardy (December 2014-November 2017) with available kidney function tests during and off-treatment were included.